• Je něco špatně v tomto záznamu ?

A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristics

R. Ferrari, I. Ford, K. Fox, M. Marzilli, M. Tendera, P. Widimský, JP. Challeton, N. Danchin,

. 2019 ; 210 (-) : 98-107. [pub] 20190115

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044988
E-zdroje Online Plný text

NLK ProQuest Central od 2002-01-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2002-01-01 do Před 2 měsíci
Health Management Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci

Odkazy

PubMed 30771737
DOI 10.1016/j.ahj.2018.12.015
Knihovny.cz E-zdroje

BACKGROUND: About 30% of angina patients have persisting symptoms despite successful revascularization and antianginal therapy. Moreover, in stable patients, percutaneous coronary intervention (PCI) does not improve survival as compared with medical therapy alone. Trimetazidine, an antianginal agent devoid of hemodynamic effect, may help reducing symptoms and improving outcomes after PCI. The ATPCI study is investigating the efficacy and safety of adding trimetazidine to standard-of-care in angina patients who had a recent PCI. METHODS: ATPCI is a randomized, double-blind, parallel-group, placebo-controlled, event-driven study in patients with coronary artery disease having undergone PCI because of stable angina (elective PCI) or unstable angina/NSTEMI (urgent PCI). After PCI, patients were randomized to trimetazidine (35 mg bid) or placebo on top of standard-of-care including event prevention drugs and antianginal treatment. Patients will be followed for 2 to 4 years. The primary efficacy endpoint is a composite of cardiac death, hospitalization for a cardiac event and recurrence or persistence of angina. Safety events related to trimetazidine use will be monitored. RESULTS: Recruitment lasted from September 2014 to June 2016. A total of 6007 patients were enrolled (58% and 42% after elective and urgent PCI, respectively). Mean age was 61 years, 77% were males, and median durations of coronary artery disease were 1 and 5 months (if urgent or elective PCI, respectively). Almost all patients received drugs for event prevention and antianginal therapy at baseline. CONCLUSION: The ATPCI study will shed further light on the management of contemporary angina patients after PCI. Results are expected in 2019.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044988
003      
CZ-PrNML
005      
20200113081544.0
007      
ta
008      
200109s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ahj.2018.12.015 $2 doi
035    __
$a (PubMed)30771737
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ferrari, Roberto $u Cardiovascular Centre and LTTA Centre, University of Ferrara, Ferrara, Italy; Maria Cecilia Hospital, GVM Care & Research, E.S. Health Science Foundation, Cotignola, (RA), Italy. Electronic address: fri@unife.it.
245    12
$a A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristics / $c R. Ferrari, I. Ford, K. Fox, M. Marzilli, M. Tendera, P. Widimský, JP. Challeton, N. Danchin,
520    9_
$a BACKGROUND: About 30% of angina patients have persisting symptoms despite successful revascularization and antianginal therapy. Moreover, in stable patients, percutaneous coronary intervention (PCI) does not improve survival as compared with medical therapy alone. Trimetazidine, an antianginal agent devoid of hemodynamic effect, may help reducing symptoms and improving outcomes after PCI. The ATPCI study is investigating the efficacy and safety of adding trimetazidine to standard-of-care in angina patients who had a recent PCI. METHODS: ATPCI is a randomized, double-blind, parallel-group, placebo-controlled, event-driven study in patients with coronary artery disease having undergone PCI because of stable angina (elective PCI) or unstable angina/NSTEMI (urgent PCI). After PCI, patients were randomized to trimetazidine (35 mg bid) or placebo on top of standard-of-care including event prevention drugs and antianginal treatment. Patients will be followed for 2 to 4 years. The primary efficacy endpoint is a composite of cardiac death, hospitalization for a cardiac event and recurrence or persistence of angina. Safety events related to trimetazidine use will be monitored. RESULTS: Recruitment lasted from September 2014 to June 2016. A total of 6007 patients were enrolled (58% and 42% after elective and urgent PCI, respectively). Mean age was 61 years, 77% were males, and median durations of coronary artery disease were 1 and 5 months (if urgent or elective PCI, respectively). Almost all patients received drugs for event prevention and antianginal therapy at baseline. CONCLUSION: The ATPCI study will shed further light on the management of contemporary angina patients after PCI. Results are expected in 2019.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a angina pectoris $x farmakoterapie $x chirurgie $7 D000787
650    _2
$a nemoci koronárních tepen $x chirurgie $7 D003324
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a koronární angioplastika $7 D062645
650    _2
$a placebo $x terapeutické užití $7 D010919
650    _2
$a pooperační komplikace $x farmakoterapie $7 D011183
650    _2
$a recidiva $7 D012008
650    _2
$a trimetazidin $x škodlivé účinky $x terapeutické užití $7 D014292
650    _2
$a vazodilatancia $x škodlivé účinky $x terapeutické užití $7 D014665
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ford, Ian $u Robertson Centre for Biostatistics, University of Glasgow, Glasgow, Scotland.
700    1_
$a Fox, Kim $u National Heart and Lung Institute, Imperial College, ICMS Royal Brompton Hospital, London, United Kingdom.
700    1_
$a Marzilli, Mario $u Cardiovascular Medicine Division, University of Pisa, Pisa, Italy.
700    1_
$a Tendera, Michal $u Department of Cardiology and Structural Heart Disease, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
700    1_
$a Widimský, Petr $u Cardiocenter, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Challeton, Jean-Pascal $u Institut de Recherches Internationales Servier, Suresnes, France.
700    1_
$a Danchin, Nicolas $u Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou (HEGP), Department of Cardiology, Paris, France; Université Paris-Descartes, Paris, France; INSERM U-970, Paris, France.
773    0_
$w MED00000228 $t American heart journal $x 1097-6744 $g Roč. 210, č. - (2019), s. 98-107
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30771737 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113081915 $b ABA008
999    __
$a ok $b bmc $g 1483257 $s 1083661
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 210 $c - $d 98-107 $e 20190115 $i 1097-6744 $m The American heart journal $n Am Heart J $x MED00000228
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace